{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:45:02Z","timestamp":1773967502778,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.heliyon.2023.e22912","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T13:13:26Z","timestamp":1701090806000},"page":"e22912","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and safety of Bruton's tyrosine kinase inhibitors in the treatment of pemphigus: A comprehensive literature review and future perspective"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7309-4066","authenticated-orcid":false,"given":"Yekta","family":"Ghane","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nazila","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirhossein","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1657-1487","authenticated-orcid":false,"given":"Sara","family":"Sadeghi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1249-4429","authenticated-orcid":false,"given":"Azadeh","family":"Goodarzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2023.e22912_bib1","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01418","article-title":"Pemphigus: current and future therapeutic strategies","volume":"10","author":"Didona","year":"2019","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e22912_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3892\/etm.2021.10770","article-title":"Comprehensive review on the pathophysiology, clinical variants and management of pemphigus (review)","volume":"22","author":"Costan","year":"2021","journal-title":"Exp. Ther. Med."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22912_bib3","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/bjd.20623","article-title":"Bruton tyrosine kinase inhibition warrants further study for pemphigus","volume":"185","author":"Drucker","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e22912_bib4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jdermsci.2021.07.002","article-title":"A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton's tyrosine kinase inhibitor, in pemphigus","volume":"103","author":"Yamagami","year":"2021","journal-title":"J. Dermatol. Sci."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e22912_bib5","doi-asserted-by":"crossref","DOI":"10.1111\/dth.12696","article-title":"Tofacitinib as the potent treatment for refractory pemphigus: a possible alternative treatment for pemphigus","volume":"31","author":"Tavakolpour","year":"2018","journal-title":"Dermatol. Ther."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22912_bib6","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjd.20431","article-title":"Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study*","volume":"185","author":"Murrell","year":"2021","journal-title":"Br. J. Dermatol."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e22912_bib7","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1021\/acs.jmedchem.1c01170","article-title":"Discovery of reversible covalent Bruton\u2019s tyrosine kinase inhibitors PRN473 and PRN1008 (rilzabrutinib)","volume":"65","author":"Owens","year":"2022","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e22912_bib8","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.4049\/jimmunol.2001130","article-title":"Preclinical efficacy and anti-inflammatory mechanisms of action of the bruton tyrosine kinase inhibitor rilzabrutinib for immune-mediated disease","volume":"206","author":"Langrish","year":"2021","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22912_bib9","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1111\/ajd.12615","article-title":"Successful use of Bruton's kinase inhibitor, ibrutinib, to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia","volume":"58","author":"Lee","year":"2017","journal-title":"Australas. J. Dermatol."},{"issue":"16","key":"10.1016\/j.heliyon.2023.e22912_bib10","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.2169\/internalmedicine.0578-17","article-title":"Paraneoplastic pemphigus associated with B-cell chronic lymphocytic leukemia treated with ibrutinib and rituximab","volume":"57","author":"Ito","year":"2018","journal-title":"Intern. Med."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22912_bib12","doi-asserted-by":"crossref","first-page":"291-e71","DOI":"10.1111\/vde.12841","article-title":"Efficacy of a Bruton's Tyrosine Kinase Inhibitor (PRN-473) in the treatment of canine pemphigus foliaceus","volume":"31","author":"Goodale","year":"2020","journal-title":"Vet. Dermatol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e22912_bib13","doi-asserted-by":"crossref","first-page":"410-e110","DOI":"10.1111\/vde.12878","article-title":"Open trial of Bruton's tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus","volume":"31","author":"Goodale","year":"2020","journal-title":"Vet. Dermatol."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22912_bib16","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjd.20431","article-title":"Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study","volume":"185","author":"Murrell","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.heliyon.2023.e22912_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2022.100156","article-title":"Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors","volume":"5","author":"Naik","year":"2022","journal-title":"J. Transl. Autoimmun."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22912_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e22912_bib15","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1111\/bcp.13351","article-title":"A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers","volume":"83","author":"Smith","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e22912_bib17","first-page":"2","article-title":"Bruton\u2019s tyrosine kinase (Btk) inhibitor tirabrutinib prevents the development of murine lupus","volume":"9","author":"Yuko","year":"2019","journal-title":"Eur. Exp. Biol."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e22912_bib18","article-title":"An updated review of pemphigus diseases","volume":"57","author":"Malik","year":"2021","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"10.1016\/j.heliyon.2023.e22912_bib19","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/1346-8138.12486","article-title":"Japanese guidelines for the management of pemphigus","volume":"41","author":"Amagai","year":"2014","journal-title":"J. Dermatol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e22912_bib20","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e22912_bib21","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/bjd.18482","article-title":"Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect","volume":"182","author":"Chen","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.heliyon.2023.e22912_bib22","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2147\/CCID.S75908","article-title":"Management of pemphigus vulgaris: challenges and solutions","volume":"8","author":"Gregoriou","year":"2015","journal-title":"Clin. Cosmet. Invest. Dermatol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e22912_bib23","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1359-6101(99)00019-2","article-title":"Tec family of protein-tyrosine kinases: an overview of their structure and function","volume":"10","author":"Mano","year":"1999","journal-title":"Cytokine Growth Factor Rev."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e22912_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/2040620714539906","article-title":"Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib","volume":"5","author":"Aalipour","year":"2014","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.heliyon.2023.e22912_bib25","article-title":"B-cell targeted therapy of pemphigus","author":"Yamagami","year":"2022","journal-title":"J. Dermatol."},{"key":"10.1016\/j.heliyon.2023.e22912_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.662223","article-title":"Bruton's tyrosine kinase (BTK) inhibitors and autoimmune diseases: making sense of BTK inhibitor specificity profiles and recent clinical trial successes and failures","volume":"12","author":"Ringheim","year":"2021","journal-title":"Front. Immunol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023101204?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023101204?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T22:28:57Z","timestamp":1759616937000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023101204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":26,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2405844023101204"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e22912","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of Bruton's tyrosine kinase inhibitors in the treatment of pemphigus: A comprehensive literature review and future perspective","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e22912","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e22912"}}